Levolta Pharmaceuticals is an innovative, clinical-stage pharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of rheumatology, immunology and cancer. The company is driven to overcome current treatment barriers by developing products with an enhanced therapeutic index that drive customer value.
Our lead product, VOLT01, is a novel proprietary derivative of zoledronic acid (ZA). In a randomized phase II trial, VOLT01 demonstrated enhanced efficacy vs ZA alone without dose-limiting toxicities and post-dose syndrome. In a randomized phase III trial, VOLT01 demonstrated statistically significant WOMAC pain reduction at 6-months vs ZA and vs placebo in JSN 2+ patients.
Levolta Pharmaceuticals is headquartered in Bethlehem, PA and is a member organization of BioNJ and Life Sciences PA.